MONTREAL, March 22 /CNW/ -- The Company's sales increased by nearly 50%. Symbol:  CXG.A-TSXV www.clemex.com Shares Outstanding:  20 749 810 MONTREAL, March 22 /CNW Telbec/ - Clemex Technologies Inc. (TSXV: CXG.A), designer and manufacturer of Image Analysis systems and software for microscopy applications, announces today its results for the third Quarter of FY2011 ending January 31(th), 2011. For this third Quarter, sales reached $1,463,916, an increase of $473,541, (47.8%), above last year sales for the same period. The Corporation posts a Net Profit of $90,489 compared to a Net Profit of $10,886 for Q3 last year. After nine months, the Company's sales reached $3,625,676 ($2,744,065 in FY2010) and posts a Net Profit of $173,563 compared to a Net Loss of $79,272 last year. Gross Margin is at 58.8% for this quarter, slightly lower than for the same period last year at 59.5%. (stable after nine months). For this last quarter, operating expenses have increase by $190,000 ($287,000 after nine months) with the increase of sales and marketing activities as they were reduced to a minimum during the last fiscal year. Further more, the Company continues to pursue research and development of its innovative Hematology instrument. FINANCIAL HIGHLIGHTS Third Quarter Nine Months Fiscal Year 2011 2010 2011 2010 $ $ $ $ Sales 1,463,916 990,375 3,625,676 2,744,065 Gross Margin 860,300 589,157 2,203,637 1,663,847 58,8% 59,5% 60,8% 60,6% Total Operating Expenses 769,810 578,271 2,030,074 1,743,119 Net Profit (Loss) & 90,489 10,886 173,563 (79,272) Comprehensive income Net Profit (Loss) per share 0,004 - 0,008 (0,004) Over the last three months, the Company made several sales to clients from the manufacturing sector in North America and abroad such as Linamar (Canada), Snap-On Tools( USA), BorgWarner (USA), Sanoh (USA), Wescast Industries (Hungary), Exide Technologies (USA), Sherry Laboratories (USA), Interstate McBee (USA) and Caterpillar (India). The Company also concluded important sales of its PSA300, a Particle Size and Shape analyzer to Neutrogena (USA) and Actelion Pharmaceuticals in Switzerland. When asked to comment these results, Clement Forget, President and CEO of Clemex Technologies Inc. declared: "Even though the manufacturing in the United States has not yet reached its normal speed, we are assisting a renewal of laboratory equipment. For the second consecutive quarter, we have sold seven automatic MicroHardness testers, an instrument mainly used for quality control of materials. The president continued; "We have also seen a recovery of sales for the PSA300 destined to the pharmaceutical industry, which had been slower for the last 18 months. These sales are encouraging for our next fiscal year as we will be focusing on Life Sciences Industry even more with our new instrument designed for Hematology. Our short and long term perspectives are promising and we remain confident that the present fiscal year will end on a positive note as our backlog order book is very good this last quarter." About Clemex Technologies, Inc. Clemex Technologies Inc. develops, manufactures and markets image analysis systems and software used by quality control and research microscopy laboratories.  Clemex' customer base spans over many countries in America, Europe, Asia and encompasses major Research and Development Centers, prestigious Universities and large manufacturing industries in various fields including healthcare, automotive, aerospace, raw materials manufacturing, pharmaceuticals, mining and other sectors. The TSX Venture has not reviewed and does not accept responsibility for the adequacy and accuracy of this news release.     To view this news release in HTML formatting, please use the following URL: http://www.cnw.ca/en/releases/archive/March2011/22/c5419.html p bCLEMEX TECHNOLOGIES INC, /bbr/ 800 Guimond,br/ Longueuil, QC, Canada J4G 1T5, /p p Contact: /p p align="justify" Clément Forgetbr/ Tel: 450.651.6573br/ Email: a href="mailto:ir@clemex.com"ir@clemex.com/a /p

Copyright